AORT vs. NARI, IRTC, TMDX, BLCO, INSP, SLNO, PRCT, NVST, LIVN, and WRBY
Should you be buying Artivion stock or one of its competitors? The main competitors of Artivion include Inari Medical (NARI), iRhythm Technologies (IRTC), TransMedics Group (TMDX), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Soleno Therapeutics (SLNO), PROCEPT BioRobotics (PRCT), Envista (NVST), LivaNova (LIVN), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry.
Artivion vs. Its Competitors
Artivion (NYSE:AORT) and Inari Medical (NASDAQ:NARI) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, community ranking, media sentiment, profitability, valuation and dividends.
Artivion has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Inari Medical has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.
In the previous week, Artivion had 2 more articles in the media than Inari Medical. MarketBeat recorded 3 mentions for Artivion and 1 mentions for Inari Medical. Artivion's average media sentiment score of 0.92 beat Inari Medical's score of 0.76 indicating that Artivion is being referred to more favorably in the media.
Artivion presently has a consensus target price of $31.40, indicating a potential upside of 9.26%. Inari Medical has a consensus target price of $69.22, indicating a potential downside of 13.44%. Given Artivion's stronger consensus rating and higher possible upside, research analysts plainly believe Artivion is more favorable than Inari Medical.
Inari Medical received 36 more outperform votes than Artivion when rated by MarketBeat users. However, 83.33% of users gave Artivion an outperform vote while only 57.89% of users gave Inari Medical an outperform vote.
86.4% of Artivion shares are held by institutional investors. Comparatively, 91.0% of Inari Medical shares are held by institutional investors. 7.6% of Artivion shares are held by company insiders. Comparatively, 10.6% of Inari Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Inari Medical has higher revenue and earnings than Artivion. Inari Medical is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.
Artivion has a net margin of -0.22% compared to Inari Medical's net margin of -13.68%. Artivion's return on equity of 5.15% beat Inari Medical's return on equity.
Summary
Artivion beats Inari Medical on 12 of the 19 factors compared between the two stocks.
Get Artivion News Delivered to You Automatically
Sign up to receive the latest news and ratings for AORT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Artivion Competitors List
Related Companies and Tools
This page (NYSE:AORT) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy AORT Stock Free AORT Stock Alerts